Evidence map›Paper›PMID 38492433›Full record

ArticleThe International journal on drug policy2024

Barriers and advocacy needs for hepatitis C services in prisons: Informing the prisons hepatitis C advocacy toolkit.

Shelley J Walker, Lok B Shrestha, Andrew R Lloyd, Olivia Dawson, Yumi Sheehan, Julia Sheehan, Nonso B C Maduka, Joaquin Cabezas, Matthew J Akiyama, Nadine Kronfli and 1 more

Open access · greenAbstract read
In one paragraph

Article in The International journal on drug policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 6 countries.

Shelley J WalkerNational Drug Research Institute, Curtin University, Perth, Australia; Burnet Institute, Melbourne, Australia; Public Health and Preventative Medicine, Monash University, Melbourne, Australia. Electronic address: shelley.walker@curtin.edu.au.
Lok B ShresthaThe Kirby Institute, University of New South Wales (UNSW), Sydney, Australia; School of Biomedical Sciences, University of New South Wales (UNSW), Sydney, Australia.
Andrew R LloydThe Kirby Institute, University of New South Wales (UNSW), Sydney, Australia.
Olivia DawsonThe International Network on Health and Hepatitis in Substance Users (INHSU).
Yumi SheehanThe Kirby Institute, University of New South Wales (UNSW), Sydney, Australia.
Julia SheehanThe Hepatitis C Trust, London, England, UK.
Nonso B C MadukaBensther Development Foundation, Enugu, Nigeria.
Joaquin CabezasGastroenterology and Hepatology Department, University Hospital Marques de Valdecilla, Santander, Spain; Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Santander, Spain.
Matthew J AkiyamaDepartment of Medicine, Albert Einstein College of Medicine / Montefiore Medical Centre, New York, USA.
Nadine KronfliDepartment of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Québec, Canada; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
INHSU Prisons
UNSW Sydney · AUAlbert Einstein College of Medicine · USBurnet Institute · AUDevelopment Research and Projects Centre · NGMarqués de Valdecilla University Hospital · ESMcGill University Health Centre · CAThe Hepatitis C Trust · GB

Funding

Leveraging community health workers to improve SARS-CoV-2 testing and mitigation among criminal justice-involved individuals accessing a corrections-focused community-based organizationR01MD016744 · NIMHD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Matthew Akiyama · 2021 to 2026
$3.5M
Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject DrugsDP2DA053730 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2021 to 2021
$2.5M
Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants LivingR00DA043011 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2020 to 2022
$747k
Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants Living with Hepatitis C-The HCV-ACCELERATE TrialK99DA043011 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI AKIYAMA, MATTHEW · 2017 to 2018
$369k
NIDA NIH HHS DP2 DA053730NIDA NIH HHS K99 DA043011NIDA NIH HHS R00 DA043011NIMHD NIH HHS R01 MD016744
6 · The paper itself

Abstract

backgroundCarceral settings are a key focus of the 2030 WHO global hepatitis C virus (HCV) elimination goals. Despite this, access to HCV testing and treatment services in prisons remains low globally, limiting opportunities to achieve these goals. Advocacy efforts are needed to address service inequities and mobilise support for enhanced HCV programs in prisons globally. INHSU Prisons, a special interest group of the International Network on Health and Hepatitis in Substance Users (INHSU) is developing a Prisons HCV Advocacy Toolkit to address this need. Here we present findings of a mixed study to inform the development of the Toolkit.

methodsThe aim of this study was to inform the development of the Toolkit, including understanding barriers for scaling up prison-based HCV services globally and advocacy needs to address these. An online survey (n = 181) and in-depth interviews (n = 25) were conducted with key stakeholders from countries of different economic status globally. Quantitative data were statistically analysed using R Studio and qualitative data were analysed thematically. The data sets were merged using a convergent design.

resultsKey barriers for enhanced prison-based HCV services included lack of political will and action, lack of prison-based healthcare resources, and poor awareness about HCV and the importance of prison-based HCV services. These findings underscore how advocacy efforts are needed to motivate policymakers to prioritise HCV healthcare in prisons and ensure funds are available for services (including diagnostic tools and treatment, healthcare teams to implement services, and systems to measure their success). Advocacy resources to raise the awareness of policy makers, people working in the prison sector, and incarcerated populations were also identified as key to increasing HCV service uptake.

conclusionThe Toolkit has the potential to support advocacy efforts for reaching HCV elimination targets. By understanding the advocacy needs of potential Toolkit end-users, the findings can inform its development and increase its accessibility, acceptability, and uptake for a globally diverse audience.

Indexed as

Health Services AccessibilityHepatitis CPrisonsGlobal HealthHumansPatient AdvocacyPrisonersSurveys and QuestionnairesAdvocacyCarceral settingsHepatitis C eliminationHepatitis C virusPeople who inject drugsPrisons

Identifiers

PMID38492433
PMCPMC11106844
OpenAlexW4392873014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.